Neuropsychiatric aspects of anticonvulsant megaloblastic anaemia.
D000086:Acetazolamide / Q000627:therapeutic use; D000328:Adult; D000748:Anemia, Macrocytic / Q000139:chemically induced* / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005492:Folic Acid / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use; D011324:Primidone / Q000009:adverse effects* / Q000627:therapeutic use; D011602:Psychophysiologic Disorders / Q000209:etiology; D013843:Thiazines / Q000627:therapeutic use; D014805:Vitamin B 12 / Q000009:adverse effects*
D013843:Thiazines; D011324:Primidone; D010672:Phenytoin; D005492:Folic Acid; D000086:Acetazolamide; D014805:Vitamin B 12; D010634:Phenobarbital